Author : adminDate : 2021-09-14 15:00

HLB’s Chinese partner to present efficacy of rivoceranib at ESMO meeting

HLB said its Chinese partner would showcase the efficacy of its anticancer drug candidate, rivoceranib, for various indications by presenting 13 study results at the European Society for Medical Oncology (ESMO) conference.

Please refer to the following website for further details: https://www.koreabiomed.com/news/articleView.html?idxno=12140